Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 12/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864418 | 1.00 | AHCY (0.81) | AHCY | |
| Hydrochloric Acid SCHEMBL2484066 | 0.99 | AHCY (0.80) | AHCY | |
| Hydrochloric Acid SCHEMBL2412144 | 0.99 | AHCY (0.80) | AHCY | |
| SCHEMBL13825262 | 0.91 | AHCY (0.80) | AHCY | |
| Neoplanocin A SCHEMBL863873 | 0.90 | AHCY (1.00) | AHCY | |
| Neoplanocin A SCHEMBL12157269 | 0.90 | AHCY (1.00) | AHCY | |
| Neoplanocin A SCHEMBL17117192 | 0.90 | AHCY (1.00) | AHCY | |
| Neoplanocin A SCHEMBL10576831 | 0.90 | AHCY (1.00) | AHCY | |
| Neoplanocin A SCHEMBL10469277 | 0.90 | AHCY (1.00) | AHCY | |
| Neoplanocin A SCHEMBL30001474 | 0.90 | AHCY (1.00) | AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | EZH2, SUZ12, DAZAP1 | AHCY 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.